menu search

AMAM / Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences

Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the JMP Securities Life Sciences Conference and RBC Capital Markets Global Healthcare Conference taking place in New York City on May 16th and 17th, respectively. The presentations will focus on the status of Ambrx's clinical development strategy and an update on the progress of its lead clinical candidates, ARX788 and ARX517. Read More
Posted: May 11 2023, 16:23
Author Name: GlobeNewsWire
Views: 103022

AMAM News  

Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data

By Seeking Alpha
October 24, 2023

Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data

Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting more_horizontal

Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data

By Seeking Alpha
October 23, 2023

Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. I more_horizontal

Why Shares of Ambrx Biopharma Soared This Week

By The Motley Fool
September 21, 2023

Why Shares of Ambrx Biopharma Soared This Week

The company, formerly based in the Cayman Islands, is moving to Delaware. It is expected to announce trial data next week regarding two of its lead th more_horizontal

Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?

By Zacks Investment Research
August 23, 2023

Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?

Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year. more_horizontal

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

By GlobeNewsWire
July 28, 2023

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time cl more_horizontal

Ambrx to Present at Multiple Upcoming Investor Meetings

By GlobeNewsWire
May 30, 2023

Ambrx to Present at Multiple Upcoming Investor Meetings

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Con more_horizontal

Ambrx Biopharma: ARX788's Potential In Cancer Treatment Presents Promising Opportunity

By Seeking Alpha
May 20, 2023

Ambrx Biopharma: ARX788's Potential In Cancer Treatment Presents Promising Opportunity

Ambrx Biopharma's stock value has surged due to positive preliminary data from cancer-targeting clinical trials of ARX788 and ARX517. With cash reserv more_horizontal

Why Shares of Ambrx Biopharma Jumped This Week

By The Motley Fool
May 18, 2023

Why Shares of Ambrx Biopharma Jumped This Week

Ambrx's lead therapies target breast cancer and prostate cancer, two of the most common forms of cancer. The company has enough cash, it said, to fund more_horizontal


Search within

Pages Search Results: